TREM-1 as a novel immunotherapeutic target to treat pancreatic ductal adenocarcinoma

By afschroeder • September 9, 2025

Gross L, Mutisheva I, Hillen H, Robatel S, Wartenberg M, Ma F, Bäriswyl L, Lee DJ, Modlin RL, Z'graggen K, Schenk M. TREM-1 as a novel immunotherapeutic target to treat pancreatic ductal adenocarcinoma. Mol Ther Oncol. 2025 Aug 14;33(3):201034. doi: 10.1016/j.omton.2025.201034. PMID: 40917508; PMCID: PMC12410479.

Tags: Dermatology, Harbor UCLA, immunotherapy, macrophage reprogramming, myeloid cells, PDAC, Publications, TREM-1 activation

Agonistic GITR treatment enhances antitumor immune responses and suppresses tumor progression in pancreatic ductal adenocarcinoma

Robatel S, Hillen H, Mutisheva I, Müller JC, Wartenberg M, Ma F, Bäriswyl L, Evenepoel J, Scheele CLGJ, Lee DJ, Modlin RL, Kessler U, Nobis[...]

Association between out-of-pocket costs and treatment patterns in psoriasis and psoriatic arthritis: A claims-based cohort study

Roberts AM, Jeong C, Chou P, Ma EJ, Katz A, Yan MJ, Johnsen N, Nong Y, Armstrong AW. Association between out-of-pocket costs and treatment patterns[...]

Central centrifugal cicatricial alopecia is associated with longer time to diagnosis among scarring alopecias

Issa T, Klomhaus AM, Kasakevich C, Pickford J, Goh C. Central centrifugal cicatricial alopecia is associated with longer time to diagnosis among scarring alopecias. JAAD[...]